Regression of new vessels (continuous outcome): mean area of fluorescein leakage (mm2) fluorescein angiography · proliferative diabetic retinopathy
1 finding from 1 review
Presence of vitreous haemorrhaged · proliferative diabetic retinopathy
Anti‐vascular endothelial growth factor (anti‐VEGF) with or without… probably leads to lower presence of vitreous haemorrhaged compared with PRP alone (moderate certainty).
1 finding from 1 review
Need for vitrectomy · proliferative diabetic retinopathy
Anti‐vascular endothelial growth factor (anti‐VEGF) with or without… may leads to lower need for vitrectomy compared with PRP alone (low certainty).
1 finding from 1 review
Quality of life (VFQ‐25 General health) · proliferative diabetic retinopathy
1 finding from 1 review
Adverse events · proliferative diabetic retinopathy
1 finding from 1 review
Intervention not reported
Overall survival (OS) ‐ Network (subnet 1) included 19 pairwise comparisons ‐ Median · people with a confirmed diagnosis of advanced renal cell carcinoma (combined risk groups) without previous systemic anticancer therapy
The intervention showed no clear difference in overall survival (OS) ‐ Network (subnet 1) included 19 pairwise… (moderate certainty).
1 finding from 1 review
Intervention not reported
Quality of life · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Progression‐free survival (PFS) ‐ Network (subnet 1) included 5 pairwise comparisons ‐ Median · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…
1 finding from 1 review
Intervention not reported
Adverse events (grade 3 to 4) · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Time to initiation of first subsequent therapy · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
MSKCC risk group · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Overall survival (OS) ‐ Network (subnet 1) included 3 pairwise comparisons ‐ Median · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…
1 finding from 1 review
Intervention not reported
Serious adverse events (SAEs) · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Quality of life (QoL) · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Progression‐free survival (PFS) ‐ Network (subnet 1) included 7 pairwise comparisons ‐ Median · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…
1 finding from 1 review
Intervention not reported
IMDC risk groups · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and an intermediate or poor risk according to the International…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Quality of life (QoL) We reported this outcome narratively in this review. Here, long‐term results (i.e., at the end of treatment) are presented. In the comparison PAZ versus SUN, QoL was measured using FACIT‐F (score range 0‐52; higher scores rep... · people with a confirmed diagnosis of advanced renal cell carcinoma (combined risk groups) without previous systemic anticancer therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Overall survival (OS) ‐ Network (subnet 1) included 10 pairwise comparisons ‐ Median · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and an intermediate or poor risk according to the International…
1 finding from 1 review
Intervention not reported
Quality of life · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and an intermediate or poor risk according to the International…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Serious adverse events · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and an intermediate or poor risk according to the International…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found